http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022152899-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_880ba93baf6097d00136b838d27bd9a4 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
filingDate | 2022-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e33305c4180bd9551e75224d99c753bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ab00b5bdcaa9e3289f857508b5e5eaa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6203de69cc220bdc6b0791e8d7dca5b4 |
publicationDate | 2022-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2022152899-A1 |
titleOfInvention | Method for predicting the response to cdk4/6 inhibitor therapy in cancer patients |
abstract | The present invention relates to a method for predicting a response or resistance to and/or a benefit from treatment with an inhibitor of cyclin-dependent kinases 4 (CDK4/6 inhibitor) in a subject suffering from a neoplastic disease, particularly breast cancer, comprising the step of: determining in a sample obtained from said subject the expression level of at least one marker selected from the group consisting of PD-L1, PIAS2, MAP2K6, DSG3, ABCC12, IFT52, ABCB6, ABCC1, ABCA5, ABCC6, ABCC11, CHUK, SUMO1, TDG, AURKA, SMC3, IKBKG and XPC, wherein the expression level of the at least one marker is indicative for predicting the response or resistance to and/or the benefit from the treatment with the CDK4/6 inhibitor in said subject. The invention further pertains to a CDK4/6 inhibitor for use in the treatment of neoplastic disease, particularly breast cancer, in a subject, wherein the subject has been determined to have a benefit from treatment with a CDK4/6 inhibitor in a method of the invention. |
priorityDate | 2021-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 401.